Respiratory disease

Pasaca Capital and Honeywell Back Telesair with $22M Series A Round

Retrieved on: 
Tuesday, January 10, 2023

Honeywell and Telesair, Inc. , an innovator of next generation respiratory care, jointly announced today that Telesair, Inc. has closed a total of $22 million Series A round financing led by Pasaca Capital with participation from existing and new investors such as ZhenCheng Capital, Shangbay Capital, Device of Tomorrow Capital, Berkeley Catalyst Fund and Ultrastar Ventures LLC.

Key Points: 
  • Honeywell and Telesair, Inc. , an innovator of next generation respiratory care, jointly announced today that Telesair, Inc. has closed a total of $22 million Series A round financing led by Pasaca Capital with participation from existing and new investors such as ZhenCheng Capital, Shangbay Capital, Device of Tomorrow Capital, Berkeley Catalyst Fund and Ultrastar Ventures LLC.
  • “We are excited to be moving into the next step of our evolution as a company,” said Telesair CEO, Bryan Liu.
  • “Honeywell is aligned with Telesair’s mission to improve lives through innovation in digital healthcare” said Patrick Hogan, Managing Director of Honeywell Ventures.
  • Honeywell ( www.honeywell.com ) delivers industry-specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally.

Global Inhalation and Nasal Spray Generic Drugs Market Report 2022 to 2028: Rapid Rise in Asthma Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 10, 2023

The "Global Inhalation and Nasal Spray Generic Drugs Market Size, Share & Industry Trends Analysis Report By End-user, By Indication, By Distribution Channel, By Demographics, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Inhalation and Nasal Spray Generic Drugs Market Size, Share & Industry Trends Analysis Report By End-user, By Indication, By Distribution Channel, By Demographics, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Inhalation and Nasal Spray Generic Drugs Market size is expected to reach $29.9 billion by 2028, rising at a market growth of 8.5% CAGR during the forecast period.
  • Inhalation and nasal spray generic drugs refer to a family of medicines that are consumed through the nose.
  • There are two types of nasal spray viz a conventional spray and a pump spray.

Army Captain Le Roy Torres Receives New, Four-Dimensional Lung Scan in Miami

Retrieved on: 
Thursday, January 12, 2023

MIAMI, Jan. 12, 2023 /PRNewswire/ -- 4DMedical, the leading developer of functional imaging software for respiratory illness, announced that Army Captain Le Roy Torres received a four-dimensional scan using 4D's XV LVAS technology today at the University of Miami Leonard M. Miller School of Medicine. 4DMedical's XV LVAS technology, which received FDA clearance in May 2020, can help physicians accurately detect areas of high and low ventilation in all parts of the lung, during all phases of the breath, with accuracy and without the need for an invasive biopsy.

Key Points: 
  • MIAMI, Jan. 12, 2023 /PRNewswire/ -- 4DMedical, the leading developer of functional imaging software for respiratory illness, announced that Army Captain Le Roy Torres received a four-dimensional scan using 4D's XV LVAS technology today at the University of Miami Leonard M. Miller School of Medicine.
  • His symptoms and those similarly afflicted include shortness of breath, headaches, autoimmune and gastrointestinal issues, memory loss, and toxic brain injury.
  • "My scan today is a major step forward for fellow veterans who are suffering from burn pit exposures and are desperate for answers," said Captain Le Roy Torres.
  • Moving forward, the detailed information provided by the XV LVAS report will help doctors shape and improve Captain Torres' health care options.

Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

Retrieved on: 
Wednesday, January 11, 2023

REYKJAVIK, Iceland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab).

Key Points: 
  • REYKJAVIK, Iceland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab).
  • The study will assess the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult subjects.
  • “We are delighted with the progress of the AVT05 development program,” said Joseph McClellan, Chief Scientific Officer.
  • Alvotech’s first marketed product, a biosimilar to Humira® (adalimumab), has been launched in Europe and Canada, and approved in 35 countries world-wide.

Icosavax Provides Corporate Update and Anticipated Milestones for 2023

Retrieved on: 
Friday, January 6, 2023

“We enter 2023 energized by the recent six-month immunogenicity data from our IVX-121 Phase 1/1b study, which we believe provides the first clinical evidence of potential differentiation on durability using Icosavax’s VLP platform technology,” said Adam Simpson, Chief Executive Officer of Icosavax. “With the Phase 1 trial of IVX-A12 -- our differentiated, bivalent vaccine combination of IVX-121 for RSV and IVX-241 for hMPV -- on track to report topline results in mid-2023, and with our plans to initiate a Phase 2 study of IVX-A12 in the second half of the year, I believe we are poised to make further strides towards our vision of creating pan-respiratory vaccines for older adults.”

Key Points: 
  • “We enter 2023 energized by the recent six-month immunogenicity data from our IVX-121 Phase 1/1b study, which we believe provides the first clinical evidence of potential differentiation on durability using Icosavax’s VLP platform technology,” said Adam Simpson, Chief Executive Officer of Icosavax.
  • These data provided the first clinical evidence of potential differentiation on durability with the company’s VLP platform technology.
  • In October, Icosavax announced the initiation of a Phase 1 trial of IVX-A12 – the only bivalent vaccine candidate targeting RSV and human metapneumovirus (hMPV) to reach clinical development.
  • In January 2023, Icosavax appointed Jennifer Raymond as SVP, Technical Operations.

Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants

Retrieved on: 
Thursday, January 5, 2023

Nirsevimab would be the first broadly protective option against RSV disease designed for all infants, if approved

Key Points: 
  • Nirsevimab would be the first broadly protective option against RSV disease designed for all infants, if approved
    Paris, January 5, 2023.
  • The Prescription Drug User Fee Act date, the FDA target action date for their decision, is in the third quarter of 2023.
  • “This is a landmark file acceptance in the US as it brings us one step closer to offering the first and only broadly protective option against RSV disease designed for all infants.
  • Nirsevimab also demonstrated a comparable safety and tolerability profile to palivizumab in the Phase 2/3 MEDLEY trial.7-9

Oxygen Concentrators Global Market Report 2022: Featuring AirSep, DeVilbiss, O2 Concepts, Philips Healthcare & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022

This report on global oxygen concentrators studies the market in terms of various types and applications.

Key Points: 
  • This report on global oxygen concentrators studies the market in terms of various types and applications.
  • Preference for healthier lifestyle and technological advancement in the components of oxygen concentrators help in the market penetration of oxygen concentrators.
  • In line with the scope of the report the various products consists of fixed oxygen concentrators and portable oxygen concentrators.
  • European market growth is favored by increasing elderly population suffering with airway tract complications thus resulting in demand for oxygen concentrators.

Jahaira L. Serrano, MD is recognized by Continental Who's Who

Retrieved on: 
Friday, January 6, 2023

ARECIBO, Puerto Rico, Jan. 6, 2023 /PRNewswire/ -- Jahaira L. Serrano, MD, FACCP, is being recognized by Continental Who's Who as a Distinguished Healthcare Provider in the medical field and for her contributions at Serrano Pulmonary Services.

Key Points: 
  • ARECIBO, Puerto Rico, Jan. 6, 2023 /PRNewswire/ -- Jahaira L. Serrano, MD, FACCP, is being recognized by Continental Who's Who as a Distinguished Healthcare Provider in the medical field and for her contributions at Serrano Pulmonary Services.
  • Dr. Serrano completed an Internal Medicine residency in 2005 and Pulmonary Medicine Fellowship in 2007, both at the University of Puerto Rico University District Hospital.
  • Dr. Serrano treats patients at Serrano Pulmonary Services, located at 702 Ave San Luis, Suite 129 in Arecibo, Puerto Rico.
  • Dr. Serrano would like to dedicate this honor to her mother, Mrs. Maria Dominguez, and her mentors, Ruth Santos, MD, and Yohana de Jesús, MD.

Marpai Introduces Chronic Condition Management to Improve Outcomes for Employer Health Plan Members

Retrieved on: 
Thursday, January 5, 2023

NEW YORK, Jan. 5, 2023 /PRNewswire/ -- Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an AI-technology company transforming self-funded employer health plans, introduces Marpai Chronic Condition Management to improve the care journey of members with chronic conditions like heart disease, respiratory disease, diabetes, kidney disease and mental health. This is the latest addition to Marpai's Clinical Services Ecosystem – proven, clinical care solutions, backed by outcome and quality data, delivering specialized strategies and support to manage costly conditions. Leveraging the most advanced artificial intelligence, Marpai's proprietary clinical matchmaking platform identifies at-risk health plan members where a clinical intervention can make a meaningful difference and connects them to an appropriate solution in the Clinical Services Ecosystem. By addressing costly conditions early and appropriately, Marpai aims to create healthier lives and reduce health plan costs for employers.

Key Points: 
  • Marpai adds clinical solution focused on effectively managing chronic health conditions to improve health outcomes, trajectories and plan costs
    NEW YORK, Jan. 5, 2023 /PRNewswire/ -- Marpai, Inc .
  • ("Marpai" or the "Company") (Nasdaq: MRAI), an AI-technology company transforming self-funded employer health plans, introduces Marpai Chronic Condition Management to improve the care journey of members with chronic conditions like heart disease, respiratory disease, diabetes, kidney disease and mental health.
  • Marpai Chronic Condition Management is available to current health plan members upon plan renewal and all new members.
  • Marpai Chronic Condition Management is part of the Marpai Cares offering which is available to all health plan members under Marpai's administration.

CGTN: New Approaches : How China pushes COVID-19 vaccine R&D and inoculation

Retrieved on: 
Tuesday, December 20, 2022

It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.

Key Points: 
  • It made substantial progress of vaccine development in five different technologies including inactivated vaccine, viral vector vaccine, recombinant protein vaccine, live attenuated influenza vaccine and nucleic acid vaccine.
  • Three years into pandemic, China has approved 13 COVID-19 vaccines, including five inactivated vaccines, five recombinant protein vaccines, two viral vector vaccines and one live attenuated influenza vaccine.
  • China also has the most inoculation plans for its domestically developed COVID-19 vaccines that are based on inactivated virus, viral vector and recombinant protein.
  • China, with a population of 1.4 billion, has had administered nearly 3.46 billion doses of COVID-19 vaccines nationwide and provided over 2 billion doses worldwide.